Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Phase II Trial 100%
• Second-line Therapy 100%
• Overall Response Rate 66%
• United States 33%
• Progression-free Survival 33%
• Diarrhea 33%
• Nausea 33%
• No Significant Difference 33%
• Japan 33%
• Median Overall Survival 33%
• Chemotherapy 33%
• Phase II Study 33%
• Previously Treated 33%
• 1-year Survival 33%
• Histological Subtypes 33%
• Stable Disease 33%
• Consecutive Days 33%
• Disease Control Rate 33%
• Treatment Side Effects 33%
• Asian Population 33%
• Previously Treated Patients 33%
• Novel Formulations 33%
• Oral Fluoropyrimidine 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Phase II Trials 100%
• Disease 33%
• Progression Free Survival 16%
• Diarrhea 16%
• Nausea 16%
• Overall Survival 16%
• Chemotherapy 16%
• Side Effect 16%
• Fluoropyrimidine 16%
• Novel Formulation 16%